Industry Growth Insights published a new data on “Endocannabinoid System Targeted Therapeutics Market”. The research report is titled “Endocannabinoid System Targeted Therapeutics Market research by Types (Oral, Inhalation, Others), By Applications (Autoimmune Disorders, Genetic Disorders, Neurological Disorders, Pain Disorders), By Players/Companies GW Pharmaceuticals, MAKScientific, Corbus Pharmaceuticals, Tilray, Pure Green, Avicanna, GB Sciences, Botanix Pharmaceuticals, Therapix Biosciences, Zelira Therapeutics”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Endocannabinoid System Targeted Therapeutics Market Research Report
By Type
Oral, Inhalation, Others
By Application
Autoimmune Disorders, Genetic Disorders, Neurological Disorders, Pain Disorders
By Companies
GW Pharmaceuticals, MAKScientific, Corbus Pharmaceuticals, Tilray, Pure Green, Avicanna, GB Sciences, Botanix Pharmaceuticals, Therapix Biosciences, Zelira Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
203
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Endocannabinoid System Targeted Therapeutics Market Report Segments:
The global Endocannabinoid System Targeted Therapeutics market is segmented on the basis of:
Types
Oral, Inhalation, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Autoimmune Disorders, Genetic Disorders, Neurological Disorders, Pain Disorders
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GW Pharmaceuticals
- MAKScientific
- Corbus Pharmaceuticals
- Tilray
- Pure Green
- Avicanna
- GB Sciences
- Botanix Pharmaceuticals
- Therapix Biosciences
- Zelira Therapeutics
Highlights of The Endocannabinoid System Targeted Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Inhalation
- Others
- By Application:
- Autoimmune Disorders
- Genetic Disorders
- Neurological Disorders
- Pain Disorders
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Endocannabinoid System Targeted Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Endocannabinoid System Targeted Therapeutics is a new class of therapeutics that uses cannabinoids to treat medical conditions.
Some of the major players in the endocannabinoid system targeted therapeutics market are GW Pharmaceuticals, MAKScientific, Corbus Pharmaceuticals, Tilray, Pure Green, Avicanna, GB Sciences, Botanix Pharmaceuticals, Therapix Biosciences, Zelira Therapeutics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Endocannabinoid System Targeted Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Endocannabinoid System Targeted Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Endocannabinoid System Targeted Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Endocannabinoid System Targeted Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Endocannabinoid System Targeted Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Endocannabinoid System Targeted Therapeutics Market Size and Y-o-Y Growth
4.5.2 Endocannabinoid System Targeted Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Endocannabinoid System Targeted Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Endocannabinoid System Targeted Therapeutics Market Size Forecast by Type
5.2.1 Oral
5.2.2 Inhalation
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Endocannabinoid System Targeted Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Endocannabinoid System Targeted Therapeutics Market Size Forecast by Applications
6.2.1 Autoimmune Disorders
6.2.2 Genetic Disorders
6.2.3 Neurological Disorders
6.2.4 Pain Disorders
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Endocannabinoid System Targeted Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Endocannabinoid System Targeted Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Endocannabinoid System Targeted Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Endocannabinoid System Targeted Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Endocannabinoid System Targeted Therapeutics Market Size Forecast by Type
9.6.1 Oral
9.6.2 Inhalation
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Endocannabinoid System Targeted Therapeutics Market Size Forecast by Applications
9.10.1 Autoimmune Disorders
9.10.2 Genetic Disorders
9.10.3 Neurological Disorders
9.10.4 Pain Disorders
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Endocannabinoid System Targeted Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Endocannabinoid System Targeted Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Endocannabinoid System Targeted Therapeutics Market Size Forecast by Type
10.6.1 Oral
10.6.2 Inhalation
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Endocannabinoid System Targeted Therapeutics Market Size Forecast by Applications
10.10.1 Autoimmune Disorders
10.10.2 Genetic Disorders
10.10.3 Neurological Disorders
10.10.4 Pain Disorders
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Endocannabinoid System Targeted Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Endocannabinoid System Targeted Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Endocannabinoid System Targeted Therapeutics Market Size Forecast by Type
11.6.1 Oral
11.6.2 Inhalation
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Endocannabinoid System Targeted Therapeutics Market Size Forecast by Applications
11.10.1 Autoimmune Disorders
11.10.2 Genetic Disorders
11.10.3 Neurological Disorders
11.10.4 Pain Disorders
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Endocannabinoid System Targeted Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Endocannabinoid System Targeted Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Endocannabinoid System Targeted Therapeutics Market Size Forecast by Type
12.6.1 Oral
12.6.2 Inhalation
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Endocannabinoid System Targeted Therapeutics Market Size Forecast by Applications
12.10.1 Autoimmune Disorders
12.10.2 Genetic Disorders
12.10.3 Neurological Disorders
12.10.4 Pain Disorders
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Endocannabinoid System Targeted Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Endocannabinoid System Targeted Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Endocannabinoid System Targeted Therapeutics Market Size Forecast by Type
13.6.1 Oral
13.6.2 Inhalation
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Endocannabinoid System Targeted Therapeutics Market Size Forecast by Applications
13.10.1 Autoimmune Disorders
13.10.2 Genetic Disorders
13.10.3 Neurological Disorders
13.10.4 Pain Disorders
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Endocannabinoid System Targeted Therapeutics Market: Competitive Dashboard
14.2 Global Endocannabinoid System Targeted Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GW Pharmaceuticals
14.3.2 MAKScientific
14.3.3 Corbus Pharmaceuticals
14.3.4 Tilray
14.3.5 Pure Green
14.3.6 Avicanna
14.3.7 GB Sciences
14.3.8 Botanix Pharmaceuticals
14.3.9 Therapix Biosciences
14.3.10 Zelira Therapeutics
